Alpha arbutin for cosmetics

About Aplha Arbutin

Alpha Arbutin is the active substance originated from natural plant which can whiten and lighten skin. Alpha Arbutin Powder can infiltrate into the skin quickly without affecting the concentration of cell multiplication and effectively prevent activity of tyrosinase in the skin and the forming of melanin. By combined arbutin with tyrosinase, decomposition and drainage of melanin are accelerated, splash and fleck can be got ride of and no side effects are caused.Arbutin Powder is one of the safest and most efficient whitening materials that are popular at present. Alpha Arbutin is also the most competitive whitening activity in the 21st century.

Alpha-arbutin is similar to β-arbutin, which inhibits the production and deposition of melanin and eliminates spots and freckles. Studies have shown that α-arbutin can inhibit the activity of tyrosinase at a lower concentration, and its inhibition of tyrosinase is better than that of β arbutin.

Alpha arbutin main function:1. Cosmetic Field Function.

(1) Alpha arbutin powder can protect the skin against damage caused by free radicals.have the function of anti-aging

(2) Alpha arbutin powder is a skin whitening agent

(3) Alpha arbutin powder inhibits the formation of melanin pigment by inhibiting Tyrosinase activity. 

2.Medical Field Function

(1) Alpha arbutin powder was first used in medical areas as an anti-inflammatory and antibacterial agent.

(2) Alpha arbutin powderwas used particularly for cystitis, urethritis and pyelitis.

(3) Alpha arbutin powder may be used to repress the virulence of bacterial pathogens and to prevent contaminating bacteria.

(4) Alpha arbutin powder is used for treating allergic inflammation of the skin .

Alpha arbutin application:

1.Alpha arbutin can be used in cosmetic field.
1.Alpha arbutin can be used in medical field.

References:

  1. 1.Salata O. Applications of nanoparticles in biology and medicine. J. Nano Biotechnology. 2004;2:3.
  2. 2.Seo D-H, Jung J-H, Lee J-E, Jeon E-J, Kim W, Park C-S. Biotechnological production of arbutins (α- and β-arbutins), skin-lightening agents, and their derivatives. Appl Biochem Biotechnol. 2012;95:1417–25.
  3. 3.Wang A-C, Cheng S-H, Sheu C, Kwan C-C. Simultaneous determination of five whitening agents by ion-pair reversed-phase high performance liquid chromatography. Int J Appl Sci Eng. 2011;9(4):287–99.
  4. 4.Dudhani AR, Kosaraju SL. Bioadhesive chitosan nanoparticles: preparation and characterization. J. Carbohydr Polym. 2010;81:243–51.
  5. 5.Gan Q, Wang T. Chitosan nanoparticle as protein delivery carrier—systematic examination of fabrication conditions for efficient loading and release. J Colloid Surface B. 2007;59(1):24–34.
  6. 6.Elsaesser A, Howard CV. Toxicology of nanoparticles. Int J Nanomedicine. 2012;64:129–37.
  7. 7.Leelapornpisid P, Leesawat P, Natakarnkitkul S, Rattanapanadda P. Application of chitosan for preparation of arbutin nanoparticles as skin whitening. J Metals, Mater Miner. 2010;20(3):101–5.
  8. 8.Sugimoto K, Nishimura T, Nomura K, Sugimoto K, Kuriki T. Inhibitory effects of α-arbutin on melanin. Synthesis in cultured human melanoma cells and a three dimensional human skin model. Bio Pharm Bull. 2004;32(3):367–73.
  9. 9.Anitha A, Maya S, Deepa N, Chennazhi KP, Nair SV, Jayakumar R. Curcumin-loaded N,O-carboxymethyl chitosan nanoparticles for cancer drug delivery. J. Biomater. Sci. 2012;23(11):1381–400. 
  10. 10.Pati F, Adhikari B, Dhara S. Development of chitosan & tripolyphosphate fibers through pH dependent ionotropic gelation. J Carbohydrate Res. 2011;346(2582–2588)
  11. 11.Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonso MJ. Chitosan nanoparticles as delivery systems for doxorubicin. J Control Release. 2001;73(2–3):255–67.
  12. 12.Liu C-Q, Deng L, Zhang P, Zhang S-R, Liu L, Xu T, et al. Screening of high α-arbutin producing strains and production of α-arbutin by fermentation. J Microb Biotechnol. 2013;29(8):1391–8.
  13. 13.Arezou G, Soleiman M, Fatemeh T, Farid T. Synthesis and optimization of chitosan nanoparticles: potential applications in nanomedicine and biomedical engineering. J Intern Med. 2014;5(3):156–61.
  14. 14.Yassin EB, Anwer MK, Mowafy HA, Elbagory IM, Bayomi MA, Alsarra IA. Optimization of 5-fluorouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer. Int J Med Sci. 2010;7:398–408.
  15. 15.Zhao L-M, Shi L-E, Zhang Z-L, Chen J-M, Shi D-D, Yang J, et al. Preparation and application of chitosan nanoparticles and nanofibers. Braz J Chem. 2011;28(3):353–62.
  16. 16.Manoj KS, Sunil KP, Alok M, Neha R, Chitosan RS. A novel excipient in pharmaceutical formulation: a review. Int J Pharma Sci and Research. 2017:2266–77.
  17. 17.Alia ME, Lamprecht A. Spray freeze drying as an alternative technique for lyophilization of polymeric and lipid-based nanoparticles. Int J Pharm. 2017;516:170–7.
  18. 18.Se KK, Niranjan R. Enzymatic production and biological activities of chitosan oligosaccharides (COS): a review. Carbohydr Polym. 2005;62:357–68.
  19. 19.Papadimitriou S, Bikiaris D, Avgoustakis K, Karavas E, Georgarakis M. Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbohydr Polym. 2008;73:44–54.
  20. 20.Van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan for mucosal vaccination. Adv Drug Deliv Rev. 2001;52(2):139–44.
  21. 21.ClaraM, RuoL, GianlucaC.Chitosan nanoparticles as therapeutic protein nanocarriers: the effect of pH on particle formation and encapsulation efficiency. Volume 34: 9, pp. 1538–1545(8) (2013).
  22. 22.Kazuhisa Sugimoto, Takahisa Nishimura, Koji Nomura, Kenji Sugimoto, and TakashiKuriki. Syntheses of arbutin-a-glycosides and a comparison of their inhibitory effects with those of a-arbutin and arbutin on human tyrosinase. Chem Pharm Bull51(7) 798—801 (2003).
  23. 23.Anarjan N, Jafarizadeh-Malmiri H, Nehdi IA, Sbihi HM, Al-Resayes SI, Tan CP. Effects of homogenization process parameters on physicochemical properties of astaxanthin nanodispersions prepared using a solvent diffusion technique. Int J Nanomedicine. 2015:1109.
  24. 24.Antonio R, Massimiliano B, Paolo BB, Bellicha AC. Chitosan nanoparticles: preparation, size evolution and stability. Int J Pharm. 2013;455(1–2):219–28.
  25. 25.Ghadiria M, Fatemi S, Vatanara A, Doroudb D, Najafabadib AR, Darabib M, et al. Loading hydrophilic drug in solid lipid media as nanoparticles: statistical modeling of entrapment efficiency and particle size. J Pharma. 2012;424:128–37. 
  26. 26.Sivakumar SM. Pharmaceutical aspects of chitosan polymer. Int J Pharm and Tech. 2013:6–12.
  27. 27.Singla AK, Chawla M. Chitosan: some pharmaceutical and biological aspects. J Pharm Pharmacol. 2001;53:1047–67.
  28. 28.Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release. 2004;100(1):5–28.
  29. 29.Illum L. Nanoparticulate systems for delivery of drugs: a real improvement over simple systems. IntJ Pharma Sci. 2007;96:473.
  30. AS, Makhijac DT, Nikamd Y, Guded RP, et al. Chitosan, and liposomes: a skin penetration study. Int J Pharm. 2015;490:391–403.
  31. 31.Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev. 2001;47(1):39–54.
  32. 32.Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y. Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm Res. 1996;13(6):896–901.

发表评论

电子邮件地址不会被公开。 必填项已用*标注